anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In patients with dilated cardiomyopathy (heart is weakened and enlarged), the presence of anti-beta1-receptor autoantibodies has been shown to predict more depressed left ventricular function, increased prevalence of serious ventricular arrhythmias, sudden cardiac death, and cardiovascular mortality. In animal models, COR-1 cyclopeptide has been shown to bind to, and therefore decrease, the anti-beta1-receptor autoantibody titre. This study will investigate the safety and effectiveness of COR-1 treatment in patients with dilated cardiomyopathy. This study will be a randomized (the study treatment is assigned by chance), double-blind, (neither investigator nor patient knows the treatment that the volunteer receives), multicenter (study is conducted in more than one center) placebo-controlled (one of the treatments is inactive), parallel group study (patients in different treatment groups receive medication at the same time) in men and women who have heart failure due to dilated cardiomyopathy. Eligible patients should also have a left ventricular ejection fraction of less than or equal to 45% (measurement of the percentage of blood leaving the heart each time it contracts) and should be positive for anti-beta1-receptor autoantibodies. The study will consist of 3 phases: a screening phase, a double-blind treatment period, and a follow-up phase. Patients will be randomly assigned to 1 of 4 treatment groups: 20 mg COR-1, 80 mg COR-1, 160 mg COR-1, or placebo (inactive medication). Each patient will receive 1 intravenous dose (medication is injected into a vein) every 4 weeks for a total of 6 months. Patients will come to the study center each time they receive study medication and will remain at the center for 2 to 3 hours following the injection. Blood samples will be drawn at time points during the screening, treatment, and follow-up periods. Patients will return to the study center for follow-up visits at 3 months following completion of the 6-month treatment period. Patients will participate in the study for approximately 9 months. Patient safety will be monitored. The study drug (COR-1) is being investigated for the treatment of heart failure.
Genome-wide association studies (GWASs) have identified hundreds of risk loci for coronary artery disease (CAD). However, non-European populations are underrepresented in GWASs, and the causal gene-regulatory mechanisms of these risk loci during atherosclerosis remain unclear. We incorporated local ancestry and haplotypes to identify quantitative trait loci for expression (eQTLs) and splicing (sQTLs) in coronary arteries from 138 ancestrally diverse Americans. Of 2,132 eQTL-associated genes (eGenes), 47% were previously unreported in coronary artery; 19% exhibited cell-type-specific expression. Colocalization revealed subgroups of eGenes unique to CAD and blood pressure GWAS. Fine-mapping highlighted additional eGenes, including TBX20 and IL5. We also identified sQTLs for 1,690 genes, among which TOR1AIP1 and ULK3 sQTLs demonstrated the importance of evaluating splicing to accurately identify disease-relevant isoform expression. Our work provides a patient-derived coronary artery eQTL resource and exemplifies the need for diverse study populations and multifaceted approaches to characterize gene regulation in disease processes.
The DU was defined when the PdetQmax was less than 20 cmH2O, the Qmax was less than 15 mL/s, and the bladder voiding efficiency (BVE) was less than 90 %. BVE = voided volume / (voided volume+ PVR) x 100%.
Participants in this iNHL arm received an intravenous infusion of obinutuzumab 1600 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 800 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.
STUDY DESIGN: This will be a randomized, placebo-controlled crossover study where patients will receive an evening dose of either aclidinium/formoterol (ACL/FOR) or placebo after steady-state conditions on twice-daily ACL/FOR have been established. Patients will continue to take the same dosage of inhaled corticosteroid (ICS) as they did prior to study entry. Subjects will complete 4 visits as part of the study, with a fifth follow-up visit if required to ensure return to pre-study health status. After an initial screening visit (Visit 1) to confirm eligibility and a 1-week run-in period on stable triple therapy \[long-acting beta2-agonist/inhaled corticosteroid (LABA/ICS) + long-acting muscarinic antagonist (LAMA)\], subjects will complete baseline testing (Visit 2) which includes: full pulmonary function tests, sleep/symptom questionnaires, and polysomnography which will include periodic measurements of overnight spirometry (sitting and supine). Subjects will then receive 2-week treatment with twice-daily ACL/FOR and continue on the same ICS as during the baseline run-in. Once stability on treatment with ACL/FOR and ICS is established, there will be two overnight treatment visits (Visits 3 and 4), conducted 3-7 days apart to allow for return to normal sleep status between. For these visits, the evening dose of ACL/FOR versus placebo will be randomized to treatment order. Treatment visits will be similar to visit 2 but will include overnight measurements of respiratory mechanics (diaphragm electromyography and respiratory pressures). Short-acting bronchodilators will be withheld for at least 8 hours prior to visits.

SAMPLE SIZE: This is an exploratory physiological study with the primary outcome being an improvement in morning pre-dose trough inspiratory capacity (IC) by 200 ml. A sample size of 20 will provide at least 80% to detect this treatment difference based on a standard deviation (SD) of approximately 0.2 L for a response difference in trough IC (vanNoord, 2006), a two-tailed test and a p\<0.05. The investigators anticipate that all patients will not consent to instrumentation; however, the investigators are hoping for n=12 with respiratory mechanical measurements. Due to the complexity of the study and its measurements, an interim analysis will be conducted after 10 subjects have been completed.
Chronic use of CELEBREX may cause an increased risk of serious adverse cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. In the APC (Adenoma Prevention with Celecoxib) trial, the hazard ratio for the composite endpoint of cardiovascular death, MI, or stroke was 3.4 (95% CI 1.4 – 8.5) for CELEBREX 400 mg twice daily and 2.8 (95% CI 1.1 – 7.2) with CELEBREX 200 mg twice daily compared to placebo. Cumulative rates for this composite endpoint over 3 years were 3.0% (20/671 subjects) and 2.5% (17/685 subjects), respectively, compared to 0.9% (6/679 subjects) with placebo treatment. The increases in both celecoxib dose groups versus placebo-treated patients were mainly due to an increased incidence of myocardial infarction [see Clinical Studies (14.7)].

All NSAIDs, both COX-2 selective and non-selective, may have a similar risk. Patients with known CV disease or risk factors for CV disease may be at greater risk. To minimize the potential risk for an adverse CV event in patients treated with CELEBREX, the lowest effective dose should be used for the shortest duration consistent with individual patient treatment goals. Physicians and patients should remain alert for the development of such events, even in the absence of previous CV symptoms. Patients should be informed about the signs and/or symptoms of serious CV toxicity and the steps to take if they occur.

There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use. The concurrent use of aspirin and CELEBREX does increase the risk of serious GI events [see Warnings and Precautions (5.4)]. 

Two large, controlled, clinical trials of a different COX-2 selective NSAID for the treatment of pain in the first 10–14 days following CABG surgery found an increased incidence of myocardial infarction and stroke [see Contraindications (4)].
Formulations and wipes for imparting a sporicide to a surface are disclosed herein. Unexpectedly, a set of naturally derived ingredients have been found to combat and treat spore-based bacteria without the use of harsh chemicals. To achieve the sporicidal efficacy of the product, botanical extracts and/or botanical-derived ingredients have been incorporated into a sporicidal formulation. Example botanical extracts that demonstrated sporicidal activity include: Garcinia morella, Setaria italica, Salvia miltiorrhiza, and Psoralea corylifolia. An example botanical-derived ingredient that demonstrated sporicidal activity included gambogic acid. Unexpectedly, use of these botanicals and/or botanical-derived ingredients on skin provided a sporicidal benefit. Other botanicals and/or botanical extracts were not found to have sporicidal efficacy.
Participants started immunosuppressive regimen consisting of low dose CsA, everolimus, MMF and CS. After week 11, the participants regimen consisted of everolimus, MMF and CS.
Cerebellar mutism syndrome (CMS) is a frequent complication of surgical intervention on posterior fossa in children. It has been only occasionally reported in adults and its features have not been fully characterized. In children and in young adults, medulloblastoma is the main reason for neurosurgery. A single case of postsurgical CMS is presented in an adult patient with a cerebellar hemorrhage and a systematic review of the published individual cases of CMS in adults was done. Literature review of individual cases found 30 patients, 18/30 (60%) males, from 20 to 71 years at diagnosis. All but one case was post-surgical, but in one of the post-surgical cases iatrogenic basilar artery occlusion was proposed as cause for CMS. The causes were: primary tumors of the posterior fossa in 16/22 (72.7%) metastasis in 3/30 (10%), ischemia in 3/30 (10%) cerebellar hemorrhage in 3/30 (10%), and benign lesions in 2/30 (6.7%) patients. 8/30 patients (26.7%) were reported as having persistent or incomplete resolution of CMS within 12 months. CMS is a rare occurrence in adults and spontaneous cerebellar hemorrhage has been reported in 3/30 (10%) adult patients. The generally accepted hypothesis is that CMS results from bilateral damage to the dentate nucleus or the dentate-rubro-thalamic tract, leading to cerebro-cerebellar diaschisis. Several causes might contribute in adults. The prognosis of CMS is slightly worse in adults than in children, but two thirds of cases show a complete resolution within 6 months.
BACKGROUND: Cyberbullying refers to a modern form of bullying that could be practiced electronically or on the Internet. This study conducted a cross-sectional survey to explore different types of cyberbullying involvement (CI) and the associations of CI with demographic characteristics and mental health problems among Chinese college students.
METHODS: A total sample of 18,578 Chinese college students were recruited (68.1 % female, mean age = 20.07 years) from October 17 to 29, 2023. All participants completed self-reported web-based questionnaires on demographic characteristics, CI, sleep disturbance, depression, anxiety, and suicidal ideation.
RESULTS: More than a quarter of participants (27.5 %) have been involved in cyberbullying: specifically speaking, 10.1 % cybervictims, 4.7 % cyberbullies, and 12.7 % both (cyberbully-victims). Males, younger age, left-behind experiences, individuals with poorer family economic status, adolescents with chronic physical illness, and those with family history of mental disorders are more likely to experience CI. Unlike participants without CI, cybervictims and cyberbully-victims reported a higher risk of sleep disturbance, depression, anxiety, and suicidal ideation. Cyberbullies also have a higher rate of sleep disturbance and depression than their peers who are not involved in cyberbullying.
CONCLUSION: Our findings indicate that CI is widespread among Chinese college students, and CI is associated with the high reported rates of a series of psychopathology. This study highlights the significance of implementing anti-cyberbullying interventions specifically targeted at college students. Furthermore, it underscores the importance of monitoring changes in students' mental health status throughout the intervention process.
To provide a cosmetic powder material that offers superior smoothness, spreadability, adherence, a natural look, and skin-blurring effects, also capable of reducing occurrence of glossiness.SOLUTION: A cosmetic powder material includes flaky base powder, a surface of which is coated with inorganic particles. The inorganic particles are calcium carbonate particles, which have a bivalent or trivalent metal salt as their core. The bivalent or trivalent metal salt is an aluminum salt. A content of the bivalent or trivalent metal salt is 0.010-0.10 pts.wt. relative to 100 pts.wt. of the flaky base powder. The calcium carbonate particles have a particle size of 0.20-5 μm. The calcium carbonate particles have a coverage of 10-50 wt.%.SELECTED DRAWING: None
The technical solution provided in the invention is that a mask is manufactured from cucumber, honey, milk powder, salt, and flour, wherein cucumber has functions of cleaning and protecting the skin, and flattening and stretching the wrinkles, and honey has a function of protecting and moistening the skin. The manufacturing method has advantages of low cost, and simple and convenient preparation. What's the most important is that the prepared mask is significant in using effect. The manufacturing method comprises: washing and paring a cucumber, cutting the cucumber into pieces, putting the pieces together with milk powder, honey and salt, which are prepared in advance, into a food processer for pulverization to prepare cucumber paste, adding flour into the cucumber paste to thicken the cucumber paste; and performing uniform stirring to obtain the mask. The mask is applied to the face after a user wash the face; a piece of preservative film is used to coat the face; and two small holes are dug for breathing. After the user lies down for a rest for 20 min, the preservative film is uncovered, and the user washes the face with clean water.
The present invention discloses a preparation method of azithromycin dispersible tablet granule coating. The granule coating process is added after mixing the materials and granulating. The coating materials are three or more selected from the group consisting of hydroxypropyl methyl cellulose, ethyl cellulose, methyl cellulose, polyvinylpyrrolidone, and polyethylene glycol. The preparation method comprises the steps of: (1) preparing the coating solution, (2) granulating, (3) coating the granules, and (4) preparing the dispersible tablets. The present invention overcomes the problems that the finished dispersible tablets are ugly in appearance caused by serious moisture absorption in the conventional preparation process of azithromycin dispersible tablets, the production cost is high, and the storage conditions are high. Thus the drug production costs are reduced. The finished products can reach moistureproof requirements by just ordinary plastic packaging. The composite membrane moistureproof protection for the finished product can be abolished.
PROBLEM TO BE SOLVED: To prepare the subject styptic having a rapid and effective styptic action, hardly causing inflammatory response, hastening intracorporeal absorption and having high wound-curing effect, by including a specific sodium carboxymethylcellulose. SOLUTION: This styptic is prepared by including sodium carboxymethylcellulose which is polyvalent (or polyhydric) carboxymethyl ether of cellulose as an active principle. The content of sodium carboxymethylcellulose is pref. 5.1-12.8 wt.% and its degree of substitution (or its degree of etherification) is pref. 0.6-1.5. When the degree of substitution is 1.0 and the primary alcohol group alone is etherified, sodium carboxymethylcellulose has a structure of the formula, and on this occasion it is the most pref. that the content of sodium salt is 8.5 wt.%. The sodium carboxymethylcellulose is pref. sterilized with electron-beam radiation to depolymerize down to a molecular weight of 200-2,000 kDa.
The present invention relates to a preparation technology and a production method for an integrated new formulation of a cassia twig-monkshood decoction, wherein the raw materials of active ingredients comprise: 12 parts by weight of tangerine peel, 12 parts by weight of bamboo shavings, 9 parts by weight of ginger, 6 parts by weight of licorice, 3 parts by weight of ginseng, and 5 parts by weight of jujube. The production process of the integrated new formulation comprises the following steps of: supersonic air-jet crushing, alcohol-water extraction, ultrasonic crushing extraction, water decocting concentration, supersonic spray drying, nanometer grinding, high pressure homogenization, nano particle preparation and the like. According to the invention, the advantages, such as multi-synergism, multi-target, embodied by a nano-carrier coupling technique, are focused to be taken of. After the integrated new formulation of tangerine peel and bamboo shavings i decoction is subjected to scale production, the production cost can be greatly reduced, the quality of products is greatly improved and the targeting property and the sustained and controlled release performance of the medicament are enhanced. The internal and external administration of the integrated new formulation of tangerine peel and bamboo shavings decoction can be realized simultaneously, and can be respectively taken in four time slices according to midnight-noon ebb-flow and qi and blood flowing rule of a human body. The integrated new formulation of tangerine peel and bamboo shavings decoction can be further prepared into films and transdermal agents which are respectively stuck to different parts of a human body according to the midnight-noon ebb-flow and qi and blood flowing rule of the human body and can be directly absorbed through skin.
PURPOSE:To provide the titled composition containing a cationic surface active agent, a higher alcohol and ethyl alcohol as essential components, giving refreshing feeling to the skin, having excellent protecting and conditioning effects to  the hair, and prepared by the emulsification process. CONSTITUTION:The titled composition contains 0.1-10.0wt% cationic surface active agent[e.g. the compound of formula (R1-R4 are alkyl, hydroxyalkyl, polyoxyethylene or benzyl; X is halogen, carboxylic acid residue, alkylsulfuric  acid residue, etc.], 0.1-20.0wt% higher alcohol (preferably a 16-20C straight- chain saturated primary alcohol) and 0.5-50.0wt% ethyl alcohol. The composition can be obtained by preparing an emulsion containing a higher alcohol and  a cationic surface active agent at 40-90 deg.C using water as a base, cooling the  emulsion to <=40 deg.C, and adding ethyl alcohol etc. to the emulsion. It is applied  preferably in the form of hair rinse, hair treatment, etc.
Participating couples of the intervention group will receive care as usual and will watch the preparatory information movie on oocyte aspiration (POAM) 1-3 days before their oocyte aspiration. Their gynecologist or midwife will empower them to watch the movie when they call them to plan the oocyte aspiration and will send them the secured link to the movie via email.
Treatment with placebo combined with vedolizumab; Subjects will receive two sachets daily of Placebo for 14 weeks. Vedolizumab will be administere as per clinical practice with the following schedule: 300 mg ev at 0, 2 and 6, 14 weeks.
A contrast agent of the formula [N(A1,A2,A3)M](counter ion(s)) for use in a diagnostic method practiced on the human or animal body, wherein N is a nitrogen atom; M is a divalent ion selected from transition metals of the group: VII, CrII, FeII, CoII, NiII and CuII; the counter ion(s) being pharmaceutically acceptable; and wherein A1, A2 and A3 are independently selected from the group of heterocyclic ligands defined in claim 1. Preferably, the contrast agent is for use as a magnetic resonance imaging contrast agent, in particular a paraCEST (Chemical Exchange-dependent Saturation Transfer) contrast agent. The contrast agent may be water-soluble. The heterocyclic ligands of the contrast agent may be coupled to a probe or label, such as an antibody, peptide, dye, such as a fluorescent compound, or a 19F probe. Also claimed is a pharmaceutical composition comprising said contrast agent and at least one pharmaceutically acceptable excipient. A method of in vitro medical imaging is also defined, especially diagnostic imaging, comprising administering said contrast agent to a sample.
This study aimed to develop and validate a nomogram to predict awakening at 1 year in patients with prolonged disorders of consciousness (pDOC). We retrospectively analyzed the data of 381 patients with pDOC at 2 centers. The data were randomly divided into training and validation sets using a ratio of 6:4. For the training set, univariate and multivariate logical regression analyses were used to identify the predictive variables. Receiver operating characteristic curves, calibration curves, and a decision curve analysis were utilized to assess the predictive accuracy, discriminative ability, and clinical utility of the model, respectively. The final model included age, Glasgow Coma Scale score, serum albumin level, and computed tomography midline shift, all of which had a significant effect on awakening after pDOC. For the 1-year awakening in the training set, the model had good discriminative power, with an area under the curve of 0.733 (95% confidence interval: 0.667-0.789). For the validation set, the area under the curve for 1-year awakening was 0.721 (95% confidence interval: 0.617-0.826). Model performance was good for both the training and validation sets according to calibration plots and decision curve analysis. We developed a precise, effective nomogram to assist clinicians in better assessing patients' outcomes, guiding clinical judgment, and personalizing the therapeutic process.
PURPOSE: To obtain a medicine containing conchiolin as an active component and having a damage curing activity and high safety to human body because of a natural substance. CONSTITUTION: This medicine contains conchiolin as an active component. Conchiolin is obtained preferably by crushing a shell of Pinctada fucata martensii, etc., removing Ca component by dilute hydrochloric acid, etc., gathering insoluble materials by a solid-liquid separation method such as a centrifuge, etc., adding purified water and collecting the insoluble materials by a filtration, etc. A hydrolyzate of conchiolin obtained by hydrolyzing conchiolin with 2-10% aqueous solution of hydrochloric acid may be used as the active component. Conchiolin is prepared to cosmetics of various formulations by adding e.g. a liquid oil such as squalene, a solid oil such as bees wax, a humectant such as glyceline.
This study aimed to assess the effects of Anti-fatigue Decoction (AFD) against central fatigue by observing the behaviors and serological indicators of rats modeled by the modified multiple platform method (MMPM) after drug intervention. Grip strength measurements were used to evaluate the muscle strength of rats. The open field test was utilized to assess anxiety-like behavior, while the Morris water maze test was conducted to evaluate the memory function of the rats. Following the behavioral assessments, rat serum samples were collected to measure the concentrations of corticosterone (CORT) and lactic acid (LAC). The concentration of LAC was determined using the colorimetric method, while the concentration of CORT was measured using the enzyme-linked immunosorbent assay (ELISA) method. Compared to the blank control group, following MMPM modeling, rats exhibited significant reductions in grip strength and impaired ability to memory. The serum analysis revealed increased levels of LAC and CORT in the model group rats. AFD can noticeably reverse these adverse changes to a certain extent. These findings highlight the positive effects of AFD and coenzymeQ10 on physical and cognitive abilities and alterations in serum biomarker levels of central fatigue rats.